Blackstone builds on Pfizer ties with $1.5bn obesity drug investment
Wednesday, November 11, 2026 · first reported by Alternatives Watch
Blackstone is investing $1.5bn in obesity drug development alongside Pfizer.
- Firm
- Blackstone
- Also named
- Pfizer
- Deal value
- $1.5B
- Asset class
- Private equity
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
See an error?
More on Blackstone
Everything on this firm →- Blackstone targets $3bn for real estate secondaries fundPrivate Equity Wire +4
- Blackstone Agreed to Invest About $535 Million in IIFL Finance for a Stake of Roughly 16% in a Rs 6,414 Crore Capital RaiseHedgeCo +3
- Blackstone Real Estate Turns to New Leaders After Meghji ExitYahoo Finance
- Dwindling Pay Fuels High-Profile Exits From Blackstone’s Marquee Real Estate TeamWSJ
- Blackstone raises $1 billion for private credit continuation fundscanx.trade
- Apollo’s £5.7bn easyJet takeover wins shareholder approvalPrivate Equity Wire
- KKR and RWE finalise $16bn UK offshore wind investmentPrivate Equity Wire +3
- Calpers doubles investment in Grain Management spectrum deal with SpaceXPrivate Equity Wire
- KPS returns to packaging sector with €2.4bn MM Packaging carve-outAlternatives Watch +1
- BC Partners to acquire Investcorp BDC at 10% discount to NAVPrivate Equity Wire
- LS Power to acquire six natural gas power-generation assets from NRG EnergyIREI
Got news? Send it to us →